France’s Sanofi to buy Synthorx for $2.5 billion

Reading Time: < 1 minute

France’s Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline.

Under the terms of the merger agreement, Sanofi has offered to buy all of the outstanding shares of Synthorx common stock for $68 per share in cash.

The $68 per share acquisition price represents a 172% premium to Synthorx’s closing price on Dec. 6, 2019.

Sanofi expects to complete the acquisition in the first quarter of 2020.

Via Reuters

Once you're here...

%d bloggers like this: